NCT07526675Recruiting
Concomitant Trans-Perineal Prostate Biopsy and Ablation (Bioblation) for Prostate Cancer
Validation of Concomitant Trans-Perineal Prostate Biopsy and Ablation (Bioblation) for Symptomatic (LUTS) Selected Most Probably Low and Intermediate Risk PCa Patients
Source: ClinicalTrials.gov · Last updated 30 Sept 2026
Brief summary (registry, in English)
This prospective study aims to validate the clinical outcomes of performing a concomitant trans-perineal prostate biopsy and laser ablation (termed "Bioblation") during a single session. The intervention is designed for symptomatic patients presenting with lower urinary tract symptoms (LUTS) who are highly suspected to have low to favorable intermediate-risk prostate cancer. By combining diagnosis and targeted treatment under local anesthesia, this approach seeks to facilitate early relief of severe symptoms and a rapid return to daily activities. Ultimately, the study evaluates whether this combined procedure decreases the patient's exposure to multiple, temporally separated interventions without compromising oncological safety or efficacy.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- First submitted
- 27 Mar 2026
- Start date
- Apr 2026
- Primary completion date
- Apr 2027
- Lead sponsor
- Benha University
- Diseases
- Prostate cancer, Childhood cancers
- NCT number
- NCT07526675
What you commit to
- Study type: Interventional
- Planned participants: 30
- From Apr 2026 to the primary completion date, Apr 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Metastatic prostate cancer
- History of lower urinary tract surgery (e.g., TURP, Laser, urinary diversions, artificial urinary sphincter)
- History of pelvic radiation therapy or radical pelvic surgery
Other
- Patient PSA level \> 20 ng/ml
- More than 3 focal lesions on MP-MRI
Who the study is looking for
- Patients with severe Lower Urinary Tract Symptoms (LUTS) meeting the following parameters:
- IPSS score \> 20
- Uroflowmetry flow rate \< 10 ml/sec
- Post-void residual \> 150 cc
- Patients most probably having low to favorable intermediate-risk prostate cancer, defined as:
- PSA level between 4 and 20 ng/ml
- MP-MRI showing 3 or fewer focal lesions
- MP-MRI focal lesions measuring \< 1.5 cm
- International or visiting patients requiring early return to their home country due to professional or personal commitments, provided they can undergo short-term management and follow-up coordination
Age in the registry: 18 months to - · Sex: Male · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Urology Department, Benha University Hospitals Coordinator of this site? Confirm its status | Banhā | Egypt | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.